Review

Vasoplegia: Mechanism and Management Following Cardiopulmonary Bypass

Volume 54 · Issue 1 · January 2022 Publish Date: February 28, 2022
Full Text PDF
DOI
Rizal Muhammad
Department of Cardiology and Vascular Medicine, Universitas Airlangga Faculty of Medicine, Dr. Soetomo General Hospital, Surabaya, Indonesia
Budi Baktijasa Dharmadjati
Department of Cardiology and Vascular Medicine, Universitas Airlangga Faculty of Medicine, Dr. Soetomo General Hospital, Surabaya, Indonesia
Eka Prasetya Budi Mulia
Department of Cardiology and Vascular Medicine, Universitas Airlangga Faculty of Medicine, Dr. Soetomo General Hospital, Surabaya, Indonesia
Dita Aulia Rachmi
Department of Cardiology and Vascular Medicine, Universitas Airlangga Faculty of Medicine, Dr. Soetomo General Hospital, Surabaya, Indonesia
Muhammad, R., Dharmadjati, B. B., Budi Mulia, E. P., & Rachmi, D. A. (2022). Vasoplegia: Mechanism and Management Following Cardiopulmonary Bypass. The Eurasian Journal of Medicine, 54(1), 92–99. https://doi.org/10.5152/eurasianjmed.2022.20394
Full Text Full Text PDF

Abstract

Vasoplegia is defined by hypotension and low systemic vascular resistance despite the normal or elevated cardiac index, a complication frequently following cardiac surgery, carrying high morbidity and mortality rate. Vasoplegia is related with a profound systemic inflammatory response and is mainly mediated by cellular hyperpolarization, a relative vasopressin deficiency, and high levels of inducible nitric oxide, following cardiopulmonary bypass. Cardiopulmonary bypass is a distinct precipitant of vasoplegia, generally due to its association with nitric oxide production and severe vasopressin depletion. Postoperative vasoplegia is usually managed with vasopressors, of which catecholamines are the traditional agents of choice. Recent studies promote the use of non-catecholamine vasopressor (vasopressin) in restoring systemic vascular resistance. Alternative agents are also able to restore vascular tone and improve vasoplegia, including methylene blue, angiotensin II, hydroxocobalamin, and ascorbic acid; however, their effect on patient outcomes is still unclear

Cite this article as: Muhammad R, Dharmadjati BB, Mulia EPB, Rachmi DA. Vasoplegia: Mechanism and management following cardiopulmonary bypass. Eurasian J Med 2022;54(1):92-99.

Similar Articles

Article Info
Published In
Journal The Eurasian Journal of Medicine
Volume / Issue Volume 54 · Issue 1 · January 2022
Pages 92-99
History
Published Online February 28, 2022
License
Copyright
Affiliations
Rizal Muhammad
Department of Cardiology and Vascular Medicine, Universitas Airlangga Faculty of Medicine, Dr. Soetomo General Hospital, Surabaya, Indonesia
Budi Baktijasa Dharmadjati
Department of Cardiology and Vascular Medicine, Universitas Airlangga Faculty of Medicine, Dr. Soetomo General Hospital, Surabaya, Indonesia
Eka Prasetya Budi Mulia
Department of Cardiology and Vascular Medicine, Universitas Airlangga Faculty of Medicine, Dr. Soetomo General Hospital, Surabaya, Indonesia
Dita Aulia Rachmi
Department of Cardiology and Vascular Medicine, Universitas Airlangga Faculty of Medicine, Dr. Soetomo General Hospital, Surabaya, Indonesia
Cite this Article
Muhammad, R., Dharmadjati, B. B., Budi Mulia, E. P., & Rachmi, D. A. (2022). Vasoplegia: Mechanism and Management Following Cardiopulmonary Bypass. The Eurasian Journal of Medicine, 54(1), 92–99. https://doi.org/10.5152/eurasianjmed.2022.20394
Share
Outlines